Published January 1, 2022 | Version v1
Journal article Open

Genome-wide CRISPR screen identifies PRC2 and KMT2D-COMPASS as regulators of distinct EMT trajectories that contribute differentially to metastasis

  • 1. Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA
  • 2. Broad Inst MIT & Harvard, Klarman Cell Observ, Cambridge, MA 02142 USA
  • 3. Koc Univ, Sch Med, Istanbul, Turkey
  • 4. Weizmann Inst Sci, Dept Mol Cell Biol, Rehovot, Israel

Description

Through genome-wide and focused CRISPR screens, Zhang et al. discover that loss of PRC2 or KMT2D-COMPASS enables distinct EMT trajectories, which exert differential effects on the metastatic capability of carcinoma cells.

Files

bib-de78b87d-8d9c-49b9-bc77-3eabc9eeb5cf.txt

Files (428 Bytes)

Name Size Download all
md5:2990d19eccdb29f979f5ea50448f1446
428 Bytes Preview Download